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Abstract
Introduction: Financial concerns are frequently cited by providers as a barrier to adult 
vaccination. This study assessed insurance reimbursements to providers for administering vaccines 
to adults in the private sector.
Methods: This study, conducted in 2018, used the 2016 MarketScan Commercial Claims and 
Encounters Database and included vaccination visits made by adults aged 19–64 years. Four 
routinely recommended vaccines targeted at adults were included: tetanus toxoid, reduced 
diphtheria toxoid, and acellular pertussis vaccine (Tdap); tetanus and diphtheria toxoids (Td); 
zoster; and influenza. The mean reimbursements for vaccine purchase and administration were 
reported and examined by state, metropolitan statistical area, provider type, and insurance plan 
type. Using the private vaccine purchase price published by the Centers for Disease Control and 
Prevention (CDC), the study reported the proportion of vaccination visits receiving 
reimbursements above the CDC-published price.
Results: The mean vaccine administration reimbursement was $25.80 for the first dose and 
$14.71 for additional doses in the same visit. The mean vaccine purchase reimbursement was 
$44.15 for Tdap, $25.78 for Td, and $216.05 for the zoster vaccine; the unweighted mean for the 
four examined influenza vaccines was $17.25. Reimbursements varied widely by state. Vaccine 
reimbursements exceeded the CDC-published price for most visits where Tdap (71.4%), zoster 
(87.8%), and three of four influenza (61.5%–88.5%) vaccines were administered but only for 
25.8% of visits where Td was given.
Conclusions: On average, reimbursements for administering vaccines to privately insured adults 
were adequate for most private practices. However, providers’ financial concerns may vary across 
geographic locations.
INTRODUCTION
Receiving recommended vaccines reduces the risk of developing vaccine-preventable 
diseases and their complications and lowers the likelihood of disease transmission because 
of herd immunity benefits.1 In the 2000s, several vaccines targeted at adults aged 19–64 
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years have been recommended by the Advisory Committee on Immunization Practices 
(ACIP). In 2005, ACIP recommended one dose of tetanus toxoid, reduced diphtheria toxoid, 
and acellular pertussis vaccine (Tdap), followed by a dose of tetanus and diphtheria toxoids 
(Td) booster every 10 years2; in 2008, one dose of zoster vaccine was recommended for 
adults aged ≥60 years,3 and in 2010, universal annual influenza vaccination was 
recommended.4 Although vaccines have been found to substantially reduce deaths and 
disabilities, uptake of the recommended vaccines among adults is not optimal.5 According to 
the 2016 National Health Interview Survey, the coverage rate for Tdap vaccine among adults 
aged 19–64 years in the past 10 years was 28%, the coverage rate for zoster vaccine among 
adults aged 60–64 years was 23.9%, and the coverage rate for influenza vaccine in the 2015–
2016 season among adults aged ≥19 years was 43.5%.6
Provider recommendation is a leading factor affecting patients’ decision to receive vaccines.
7–9
 Patients often report not receiving recommendations at provider visits.8,9 One common 
barrier to adult vaccination reported by providers is the financial burden associated with 
vaccination.10–14 A survey among general internists and family physicians indicated notable 
proportions were dissatisfied with insurance reimbursements for vaccine purchase and 
administration from both private and public payers.10 Few studies have attempted to assess 
providers’ financial concerns about providing routinely recommended vaccines to adults. 
Lindley et al.15 surveyed 104 general internal medicine and family medicine practices in 
2014 and reported that payment levels and perceived profit on adult vaccination services 
varied by payer type: A larger proportion of providers serving patients covered by preferred 
provider organizations reported making profits on adult vaccination, whereas most providers 
serving Medicaid patients reported losing money. Although focusing on vaccines 
administered to children and adolescents, Freed and colleagues16 reported that the mean 
purchase price per vaccine dose for Tdap was $34.52 (range, $29.20–$38.61), and the mean 
insurance reimbursements for a dose of Tdap was $39.80 (range, $29.74–$50.84); the mean 
vaccine administration reimbursement for the first dose was $16.62 (range, $3.87–$26.55) 
and amounted to $11.63 (range, $3.36–$37.20) for subsequent doses in the same visit. 
Though survey studies provide valuable insights into providers’ financial concerns, these 
studies are limited in the number of included practices and geographic locations, and a 
substantial proportion of providers reported limited knowledge about payments received for 
vaccination services.10,13,14 To better characterize vaccine-financing issues among 
providers, it is important to examine provider payment for adult vaccination on a broader 
scope.
This study used an insurance claims database to examine reimbursements for vaccine 
purchase and administration in the private sector. Although physician dissatisfaction on 
reimbursements differs by payer type,10,15 this study focused on the private insurance 
market as it is the most common insurance type among adults,17 and information on 
reimbursements to private providers for adult vaccination is very limited.
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METHODS
Study Sample
This study used the 2016 MarketScan Commercial Claims and Encounters (CCAE) 
Database. The CCAE contains individual-level enrollment information and medical claims 
for individuals aged ≤64 years and covered by large self-insured employers and health plans 
for all U.S. states and DC. The CCAE represents a large proportion of the U.S. privately 
insured population—about 28 million individuals (~13% of the privately insured population) 
were included in 2016.
Measures
The analysis included insurance claims for vaccination visits made by privately insured 
adults aged 19–64 years. A vaccination visit was defined as an outpatient visit with the 
Current Procedural Terminology (CPT) codes related to a vaccine/vaccines and vaccine 
administration (i.e., 90471, administration of the first vaccine dose in the visit). Visits at 
which multiple vaccines were administered may have included CPT code 90472, indicating 
administering an additional vaccine dose during the same visit; a visit was required for the 
CPT code 90471 to be included in the analysis. The outcome variables included insurance 
reimbursements for vaccine purchase and vaccine administration. Four ACIP routinely 
recommended vaccines for adults aged 19–64 years were the focus of this study: Tdap 
(90715), Td (90714), zoster live vaccine (90736), and influenza vaccine (90656, 90658, 
90686, and 90688). Although there were other CPT codes associated with influenza 
vaccines, this study focused on the four most common CPT codes, accounting for >95% of 
the insurance claims for influenza vaccine in the CCAE. Vaccination visits with vaccine or 
vaccine administration reimbursements <$2 were excluded (~4%) as the CCAE frequently 
sets the reimbursement amount to $0 or $1 for services covered by capitated insurance plans 
in which payments are made on a per-enrollee per-month basis. Administrative data are 
subject to coding and data entry errors. Although MarketScan data processors adjust the 
payment information to reflect the correct payment amount, some erroneous records may 
remain unresolved. To exclude insurance claims with unusual reimbursement amounts, the 
analysis dropped ~5% of the vaccination visits for which reimbursements for the first 
administered vaccine dose were >$87.59 (2 SDs from the mean vaccine administration 
reimbursement before this exclusion condition of $27.28—a method generally adopted by 
researchers and the Centers for Medicare & Medicaid Services to identify outliers; this 
approach eliminates values substantially inconsistent with most observations, while retaining 
a large majority of observations)18–20 or for which vaccine reimbursements were more than 
double the 2016 Centers for Disease Control and Prevention (CDC)–published private 
vaccine purchase price.21 If a vaccine CPT code was associated with more than one 
purchase price because of more than one manufacturer producing that type of vaccine, the 
average purchase price of all vaccines billed with that CPT code was used as the CDC-
published price. Finally, four states were excluded (Alaska, Hawaii, Rhode Island, and 
Vermont) because these states purchase all or selected routinely recommended vaccines for 
adults and distributed them free of cost to participating providers (providers in these states 
would not necessarily submit insurance claims to receive vaccine reimbursements).
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Statistical Analysis
The mean insurance reimbursement for the vaccine and vaccine administration was 
compared by state, metropolitan statistical area (MSA; MSA versus non-MSA), insurance 
plan type, and provider type. Insurance plans were categorized into four types: fee-for-
service plans, managed care plans (preferred provider organizations and point of service), 
capitated plans (HMO and capitated or partially capitated point of service), and high 
deductible plans (consumer-driven and high deductible health plans). The analysis 
considered seven types of healthcare providers: family physicians, internists, obstetricians 
and gynecologists, emergency physicians, nurse practitioners and physician assistants (NPs/
PAs), pharmacists, and others (e.g., pediatricians and providers in public health agencies). 
The study reported the proportion of vaccination visits at which multiple vaccines were 
administered and examined the distribution of the reimbursement amount for vaccine 
purchase and vaccine administration. The proportion of vaccination visits with vaccine 
reimbursements above the CDC-published price was reported. SAS version 9.3 was used to 
clean the data and report the results.
As a secondary analysis of data without identifiers, the study did not require IRB review.
RESULTS
This study included 2,887,132 outpatient visits with insurance claims for vaccine 
administration. Table 1 presents the mean vaccine administration reimbursement and 
proportion of vaccination visits at which multiple vaccines were administered by the state. 
The mean reimbursement amounts for the first dose and for vaccines administered after the 
first dose were $25.80 and $14.71, respectively; most vaccination visits had vaccine 
administration reimbursements around the mean (results not shown). There were large 
variations in insurance reimbursements across states, ranging from <$14.99 (South Carolina; 
Truven Analytics, which publishes MarketScan data, prohibits publication of estimates 
generated from MarketScan databases for South Carolina) to $40.40 (Oregon); South 
Carolina (<$11.22) and Oregon ($24.26) also had the lowest and highest reimbursement for 
the CPT code 90472. Overall, 8.9% (n=256,955) of the vaccination visits had multiple 
vaccines administered during the visit; at these visits, influenza (59.5%) was the most 
prevalent vaccine administered. The proportion of visits with multiple vaccines administered 
was highest in Oklahoma (13.5%) and lowest in Mississippi (5.4%). The findings did not 
show noticeable differences in vaccine administration reimbursements by MSA and 
insurance plan type (results not shown). Vaccine administration reimbursements to 
pharmacists ($17.50) and NPs/PAs ($23.51) were lower than the reimbursements to 
physicians (i.e., $27.87 for obstetricians and gynecologists, $27 for internists, $26.48 for 
emergency physicians, and $25.84 for family physicians).
Tables 2 and 3 present the mean reimbursement amount per vaccine dose and the proportion 
of vaccination visits receiving insurance reimbursements above the CDC-published private 
sector vaccine purchase price for noninfluenza and influenza vaccines, respectively. For 
Tdap, the mean vaccine dose reimbursement was $44.15; the 2016 average CDC-published 
price was $40.49. For zoster, the mean vaccine dose reimbursement was $216.05, and the 
CDC-published price was $187.89; the corresponding numbers for Td were $27.20 and 
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$29.73, respectively. Vaccine dose reimbursements higher than the CDC-published purchase 
price were received for 71.4% of Tdap vaccination visits and 87.7% of zoster vaccination 
visits; the corresponding proportion for Td was 25.8%. Figure 1 displays the distribution of 
the insurance reimbursements for the three vaccines. Although reimbursement amounts were 
clustered around the CDC-published price, the peak of the distribution was above the CDC 
price for Tdap and zoster. Reimbursement amounts varied by state, from $36.54 (Idaho) to 
$50.56 (Wisconsin) for Tdap, from $20.31 (Michigan) to $35.47 (Montana) for Td, and from 
$188.10 (Michigan) to $255.47 (Massachusetts) for zoster. The largest proportion of adult 
vaccine doses was administered by family physicians (42.4%), followed by internists 
(20.1%). For Tdap and Td, there was no significant difference in vaccine dose 
reimbursements by MSA, provider type, or insurance plan type (results not shown). For 
zoster, the mean vaccine dose reimbursement was lower for pharmacists ($206.26) and 
NPs/PAs ($209.77) compared with other types of provider; vaccine reimbursements were 
lower in non-MSAs ($213.56) than in MSAs ($216.30). By insurance plan type, fee-for-
service plans ($210.98) received the lowest, whereas managed care plans ($217.85) received 
the highest vaccine dose reimbursements.
Table 3 presents the reimbursement amount for the four most commonly billed types of 
influenza vaccines. CPT codes 90686 (n=810,914) and 90688 (n=347,719) were the most 
prevalent influenza vaccine claim codes in the data, accounting for 75.8% of the adult 
influenza vaccines; the mean reimbursement for CPT codes 90686 and 90688 was higher 
($19.68 for the CPT code 90686 and $18.57 for the CPT code 90688) than that for the CPT 
codes 90656 and 90658 ($16.66 for CPT code 90656 and $14.08 for CPT code 90658). The 
unweighted average reimbursement for these vaccines was $17.25. Mean reimbursement for 
three of the four influenza vaccines was above the CDC-published vaccine purchase price, 
and >85% of visits at which either of the two most commonly administered influenza 
vaccines were administered received vaccine reimbursements higher than the CDC-
published price. Figure 2 displays the distribution of insurance reimbursements for the four 
influenza vaccines. Reimbursements for influenza vaccine purchase were clustered around 
the price published by CDC, and the peak of the distribution for all four occurred at or above 
the CDC price. Looking at the reimbursement amount by state, the unweighted mean 
reimbursement for the four influenza vaccines ranged from $13.48 (Louisiana) to $20.23 
(Wisconsin). For the most commonly billed influenza vaccine (90686), the range of 
reimbursement was between $16.67 (Minnesota) and $23.35 (Massachusetts); Massachusetts 
was also the highest reimbursement ($22.41) state for the vaccine with the CPT code 90688. 
Reimbursement for CPT codes 90656 ($9.34) and 90658 ($9.10) was the lowest in 
Louisiana; <6% of claims in Louisiana were above the CDC-published price for those two 
influenza vaccines. The data did not show noticeable and consistent differences in influenza 
vaccine reimbursements by MSA and insurance plan type across the four vaccines. By 
provider type, reimbursements were lower for nonphysician providers: NPs/PAs received the 
lowest reimbursements for CPT code 90686 ($18.62), and pharmacists received the lowest 
reimbursements for CPT codes 90656 ($15.46), 90658 ($12.45), and 90688 ($17.82).
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DISCUSSION
This study used the 2016 MarketScan CCAE data to examine insurance reimbursements to 
private providers for administering routinely recommended adult vaccines in 46 states and 
DC. The mean reimbursement amount for five of seven vaccines included was above the 
private purchase price published by the CDC, although payments varied widely by state. 
When comparing vaccine dose and administration payments by provider type, 
reimbursement was lower for nonphysician vaccine providers than physician vaccine 
providers.
Insurance companies set their reimbursement rates for private providers based on Medicare 
reimbursement rates, which are adjusted to account for geographic variations in medical 
costs.22 This may contribute to the finding of a large variation in insurance reimbursements 
by geographic location. Other factors, such as variations in population health, healthcare 
utilization pattern, and the competition among insurance carriers within a state, are likely to 
play a role in geographic differences in reimbursements for private providers.
The mean vaccine administration reimbursement ($25.80 for the first dose and $14.71 for 
subsequent doses) and the mean reimbursement for Tdap vaccine purchase ($44.15) were 
higher than the numbers reported by Freed et al.16 The differences are likely attributable to 
differences in study methods (e.g., surveying providers versus insurance claims data), study 
samples (e.g., 89% of the practices included by Freed and colleagues were pediatric offices), 
and geographic variations (i.e., their survey covered only five states). In the report of Freed 
et al., the mean purchase price per vaccine dose for Tdap was $34.52 ($39.96 in 2016 dollars 
based on the Consumer Price Index). This number was still lower than the CDC-published 
price, $40.49. Using $39.96 as the cut off, the proportion of Tdap vaccination visits 
receiving reimbursements above the cut off increased to 74.3%.
The CDC private vaccine purchase prices are reported by vaccine manufacturers. It is 
common for private providers to pay lower than the manufacturer-reported price as private 
providers often receive discounts through participating in group purchasing, bulk ordering, 
or prompt payment.15,16 Accordingly, the proportion of vaccination visits receiving 
reimbursements above the actual vaccine purchase price is likely to be higher than what this 
study reports. Moreover, the mean vaccine administration reimbursement ($25.80) was 
substantially greater than the average total variable cost per vaccine injection ($11.51; 
$13.32 in 2016 dollars) as reported in Glazner and colleagues.23 These findings suggest that 
many private providers are likely to receive adequate insurance reimbursements. Previous 
research on payments for adult vaccination mostly comes from surveying providers, and 
their results suggest that providers are generally dissatisfied with insurance reimbursements 
for vaccination services.10–14 Using insurance claims data, this study suggests that many 
providers may profit when administering vaccines to privately insured adults. The statement 
is consistent with Lindley et al.15 that a greater proportion of private providers reported 
profiting on adult vaccination services; this may also explain why many physician practices 
reported that they rarely/never negotiated insurance payments with private insurers. 
However, financial concerns among private providers are likely to vary by location, as the 
findings showed large variations in insurance reimbursements by state. It would also vary by 
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individual practices as costs to vaccinate also include labor, vaccine storage, recovery costs 
attributable to wastage, and inventory shrinkage, among others.24
This study showed lower reimbursements for nonphysician providers, such as pharmacists 
and NPs/PAs. The adult immunization standards recommend that all types of providers 
recommend and administer vaccines to adult patients25; having lower reimbursements for 
nonphysician providers may be a disincentive to have vaccines recommended by every 
provider at every visit. Moreover, pharmacies are often present when other vaccine providers 
are scarce (i.e., rural or other provider shortage areas). Although low reimbursements do not 
necessarily result in low profits or financial losses for pharmacies (the overhead costs of 
administering vaccines in pharmacies are likely to be lower than the overhead costs in 
physician’s offices, and individuals receiving vaccines at pharmacies often make retail 
purchases that may offset the low vaccination reimbursements), increasing reimbursements 
for nonphysician providers could still improve access to adult vaccines.
The data show that influenza vaccines were the most common vaccine types administered to 
adults: About 1.5 million vaccination visits had influenza vaccine administered compared 
with about 710,000 visits for Tdap. The results were consistent with the adult vaccine 
coverage estimates generated from the 2016 National Health Interview Survey.6 Public 
campaign for influenza vaccines might increase adults’ awareness and demand for the 
vaccine. In addition, studies have shown that physicians are more likely to assess patient 
vaccination status for seasonal influenza and stock influenza vaccines.11 One reason may be 
that influenza vaccines are relatively less expensive than other vaccines recommended for 
adults, and a higher proportion of physicians report making profits on seasonal influenza 
vaccination.15
Limitations
This study is subject to some limitations. First, it considered four ACIP routinely 
recommended vaccines and was based on a convenience sample of patients aged 19–64 
years residing in 46 states and DC covered by large self-insured employers or regional health 
plans in the private insurance market. The results may not generalize to all providers 
administering adult vaccines. However, more than 2.8 million vaccination claims were 
included, with variations in geographic locations and health insurance plans. Second, the 
authors used the CDC-published vaccine purchase prices as the basis to gain insights into the 
financial well-being of private providers. Studies have shown large variations in vaccine 
purchase prices among private pediatric practices,16,26 and vaccine purchase costs in 
individual practices likely differed from the CDC price. However, no published data on 
vaccine purchase costs are available. Accordingly, this study evaluated providers’ financial 
concerns on adult vaccination at an average level rather than assessed the financial gains or 
losses of individual practices on vaccinating adults. The financial well-being of an individual 
practice would depend on practice-specific vaccine purchase costs and other related costs to 
vaccinate,16,24 as well as the mix of payers billed by that practice.
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CONCLUSIONS
Although some private practices may profit from administering vaccines to adults, 
providers’ financial well-being is likely to vary across states and individual practices. It is 
important to understand profitability of adult vaccination services at the state and local 
levels, as financial disincentives could reduce the number of providers offering adult 
vaccines and hinder the ability to improve vaccination coverage in underserved areas.
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Figure 1. 
Distribution of insurance reimbursements for selected routinely recommended adult 
vaccines.
Note: Data from the 2016 MarketScan Commercial Claims and Encounters Database. The y-
AXIS presents the proportion of insurance claims with reimbursement amount in each price 
category. The line presents the 2016 CDC-published vaccine purchase price in the private 
sector; for Tdap, this price is the average of the two vaccines listed. CPT codes for Tdap, Td, 
and zoster live vaccine are 90715, 90714, and 90736, respectively.
CDC, Centers for Disease Control and Prevention; CPT, current procedural terminology; Td, 
tetanus and diphtheria toxoids; Tdap, tetanus toxoid, reduced diphtheria toxoid, and acellular 
pertussis vaccine.
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Figure 2. 
Distribution of insurance reimbursements for adult influenza vaccines.
Note: Data from the 2016 MarketScan Commercial Claims and Encounters Database. The y-
axis presents the proportion of insurance claims with reimbursement amount in each price 
category. The line presents the 2016 CDC-published vaccine purchase price in the private 
sector; for CPT codes covering more than one influenza vaccine product, this is the average 
price of the products listed.
CDC, Centers for Disease Control and Prevention; CPT, current procedural terminology.
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